VK2735 for Weight Management Phase 3

What Was Tested

The trial (phase 3) is built around VK2735.

It had four arms (groups): Placebo Assignment (placebo comparator), one (experimental), one (experimental) and one (experimental).

VK2735 Placebo Comparator Once Weekly.

The registry classes the interventions as drug.

Who Took Part

The registry lists 4500 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18 years of age at the time of signing the informed consent. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated). Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure. BMI calculated at the Screening visit will be used to determine eligibility.

The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening); current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes); treatment with glucose-lowering agent(s) within 90 days before screening.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

The participants were allocated by chance, so the VK2735 group and the comparison group should start out alike.

The VK2735 group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on VK2735, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2025-06-23 with completion listed for 2027-07-01.

It ran at 137 sites in United States (135) and Puerto Rico (2).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment (time frame: 78 Weeks).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of VK2735 in 4500 people.

With 4500 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the VK2735 compound page, all human trials.